Welcome to the official website of Huatong Fuyuan Biology
Tel: +86 538 8937 017 | Fax: +86 538 8937 017
Current Location: Home>Products>Product Introduction
Gene recombinant monoclonal antibody series of medical injection products, mainly used in the treatment of: firstly, a variety of tumours (e.g. metastatic breast cancer, prostate cancer, giant cell bone tumours); secondly, osteoporosis; thirdly, rheumatoid arthritis and other symptoms.
1. Gene recombinant monoclonal antibody series of medical injection products, mainly used in the treatment of: firstly, a variety of tumours (such as: metastatic breast cancer, prostate cancer, giant cell bone tumours); secondly, osteoporosis; thirdly, rheumatoid arthritis and other symptoms.
2. Market prospects: the project can achieve an annual sales revenue of 12 billion yuan after reaching production, can complete the annual tax revenue of more than 1 billion yuan, and arrange technical labor employment of more than 500 people.
Related Products:
Anti-IL-17/TNFR fusion proteinAnti-IL-17/TNFR fusion protein IPR: anti-IL-17 antibody/TNFR ECD fusion protein and its uses (Patent Application No.: 201711137039.8, PCT/CN2018/114079),IL-17 and TNF-α have significant synergistic effects in cell signalling pathways and in promoting inflammatory mediators. Therefore, it is of great prospect to develop IL-17 and TNF-α bispecific antibodies for autoimmune diseases. Anti-IL-17 and TNFR fusion proteins, there are no immunogenicity problem, would be the world's first anti-IL-17 and TNF-α bispecific antibodies with better efficacy than Taltz if developed successfully.- Tumour immunotherapy antibody fusion protein BY24.3Tumor immunotherapy antibody fusion protein BY24.3 IPR: Dual-targeted fusion protein targeting PD1 or PD-L1 and targeting the VEGF family and its use (Patent Application No. 201710905683.9, PCT/CN2018/10674),The effectiveness of PD1/PD-L1 combination anti-angiogenic therapy may be based on the fact that: Improve the efficacy of PD1/PD-L1 monoclonal antibody by blocking the immunosuppressive effects of VEGF and promoting T-cell infiltration in tumour tissue. Drugs acting on the VEGF target effectively "modulate" the normalisation of tumour neovascularisation and improve the immune "desertification" of tumour tissue due to abnormal neovascularisation.
- Genetically recombinant monoclonal antibody series pharmaceutical injectionsGene recombinant monoclonal antibody series pharmaceutical injection products are mainly used to treat: first, various tumors (such as metastatic breast cancer, prostate cancer, giant cell bone tumors); second, osteoporosis; third, rheumatoid joints inflammation and other symptoms. 1. It is a series of pharmaceutical injection products of genetically recombinant monoclonal antibodies, mainly used in the treatment of: first, various tumors (such as metastatic breast cancer, prostate cancer, giant cell bone tumors); second, osteoporosis; third, Rheumatoid arthritis and other symptoms. 2. Market prospects: After the project reaches full production, it can achieve annual sales revenue of 12 billion yuan, achieve annual tax revenue of more than 1 billion yuan, and arrange for more than 500 technical labor jobs.
- Tumor immunotherapy antibody fusion protein BY24.26Intellectual property of tumour immunotherapeutic antibody fusion protein BY24.26: multi-targeted fusion protein blocking vascular endothelial cell growth and activating T cells and contained drug compositions (Patent Application No. 201910023522.6, International Patent Application No. PCT/CN2020/071213)
